AI Article Synopsis
- An out-of-office treatment for molluscum contagiosum is needed, and this study evaluates the effectiveness and safety of berdazimer gel, 10.3%, compared to a placebo vehicle over 12 weeks.
- A total of 1,598 patients participated, with berdazimer showing a significantly higher complete clearance rate (30.0%) compared to the vehicle (19.8%), and it was effective across various subgroups.
- While berdazimer demonstrated positive outcomes, it also caused mild to moderate local skin reactions, like pain and redness, and the study's limitations included a focus only on US patients and no follow-up beyond 12 weeks.
Article Abstract
Background: An out-of-office therapeutic agent indicated for molluscum contagiosum is needed.
Objective: To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide-releasing medication) versus vehicle.
Methods: Berdazimer gel, 10.3% or vehicle was applied once daily to all molluscum contagiosum lesions for 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance and partial clearance at week 12. Safety and tolerability assessment: adverse events through week 24 and local skin reactions through week 12.
Results: There were 1598 patients enrolled (n = 917 berdazimer, n = 681 vehicle). Berdazimer was superior to vehicle at week 12 in complete clearance rates, 30.0% versus 19.8% (odds ratio, 1.75; 95% CI, 1.38-2.23, P < .001). Subgroup analyses of primary efficacy showed consistent favorable efficacy for berdazimer across most subgroups, including age, sex, baseline lesion count, and disease duration. Berdazimer provided favorable outcome for partial clearance. Application-site pain (18.7% vs 4.8% in berdazimer vs vehicle) and erythema (11.7% vs 1.3%), mostly mild to moderate, were the most common local skin reactions.
Limitations: Berdazimer sodium in molluscum patients with lesions (B-SIMPLE) trials enrolled only US patients; no efficacy assessments beyond week 12.
Conclusions: Berdazimer gel, 10.3% showed favorable efficacy and safety across subgroups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2023.09.066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The safety and tolerability of berdazimer gel 10.3% in Japanese patients with molluscum contagiosum.
JAAD Int
February 2025
Sato Pharmaceutical Co., Ltd., Tokyo, Japan.
Background: Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication.
View Article and Find Full Text PDFNOS2-derived low levels of NO drive psoriasis pathogenesis.
Cell Death Dis
June 2024
Ingrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Article Synopsis
- * Researchers found that while NOS2 mRNA is strongly expressed in psoriatic skin, its protein translation is hindered by IL-17-induced miR-31, leading to lower nitric oxide (NO) levels.
- * In experiments with a psoriasis mouse model, altering NO levels through gene knockout or a NO-releasing treatment showed significant effects on psoriatic inflammation, suggesting that NO donor therapy could be a promising new treatment for psoriasis.
Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis.
Pediatr Dermatol
May 2024
Novan, Inc., Durham, North Carolina, USA.
Article Synopsis
- The study examined the effectiveness and safety of berdazimer gel, a topical antiviral treatment, in controlling molluscum contagiosum (MC) infections in patients with and without atopic dermatitis (AD).
- It involved a combined analysis of three Phase 3 clinical trials, where patients applied berdazimer or a placebo daily for 12 weeks, measuring the complete clearance of lesions as the primary outcome.
- Results indicated higher clearance rates for berdazimer compared to the placebo in both subgroups, though some application-site adverse effects were noted, particularly in patients with concurrent AD.
Berdazimer Topical Gel, 10.3%: First Approval.
Drugs
March 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Article Synopsis
- Berdazimer topical gel, 10.3% (ZELSUVMI™) is a new treatment for molluscum contagiosum developed by Novan Inc., utilizing a unique nitric oxide (NO) technology (NITRICIL™).
- It was officially approved in January 2024 for use in both adults and children aged 1 year and older in the USA.
- The article details the significant milestones and progress made during the development of this topical gel leading to its approval.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!